Literature DB >> 22134071

Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer.

Yuko Minami-Shimmyo1, Yuichiro Ohe, Seiichiro Yamamoto, Minako Sumi, Hiroshi Nokihara, Hidehito Horinouchi, Noboru Yamamoto, Ikuo Sekine, Kaoru Kubota, Tomohide Tamura.   

Abstract

INTRODUCTION: The aim of the study is to evaluate the current status of treatment-related death (TRD) in lung cancer patients.
METHODS: We retrospectively analyzed the incidence and risk factors of TRD in lung cancer patients who received chemotherapy and/or thoracic radiotherapy using logistic regression analyses.
RESULTS: Between January 2001 and December 2005, 1225 (222 small cell and 1003 non-small cell lung cancers) patients received chemotherapy and/or thoracic radiotherapy as the initial treatment. Of these, 43 patients receiving chemotherapy followed by thoracic radiotherapy were included into both the chemotherapy-alone and radiotherapy-alone groups. There were a total of 23 (1.9%) TRDs. Chemotherapy-related deaths occurred in 7 of 927 (0.8%) patients, including 4 from drug-induced lung injury, 2 from pneumonia, and 1 from unknown cause. Concurrent chemoradiotherapy-related deaths occurred in 12 of 245 (4.9%) patients, including 11 from radiation pneumonitis and 1 from pneumonia. Thoracic radiotherapy-related deaths occurred in 4 of 96 (4.2%) patients. The incidence of chemotherapy-related death was correlated with poor performance status (odds ratio [OR]: 11.4, 95% confidence interval [CI]: 3.53-37.1), the presence of hypoxia (OR: 19.3, CI: 6.06-61.7), hyponatremia (OR: 45.5, CI: 13.4-154), and treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (OR: 8.56, CI: 2.48-29.5), whereas the incidence of concurrent chemoradiotherapy-related death was correlated with pulmonary fibrosis (OR: 22.2, CI: 5.61-87.8). Radiotherapy results were not analyzed because there were too few patients.
CONCLUSIONS: TRD occurred in 1.9% of the patients as a result of treatment-related lung injury in the majority of the cases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22134071     DOI: 10.1097/JTO.0b013e31823c4c07

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  26 in total

1.  Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: a randomized, placebo-controlled study.

Authors:  Pengtao Bao; Weiguo Zhao; Yun Li; Yu Liu; Yi Zhou; Changting Liu
Journal:  Med Oncol       Date:  2014-12-12       Impact factor: 3.064

Review 2.  Capacity of gold nanoparticles in cancer radiotherapy.

Authors:  Nadeem M S Nagi; Yasir A M Khair; Ahmed M E Abdalla
Journal:  Jpn J Radiol       Date:  2017-08-09       Impact factor: 2.374

3.  Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Yuko Tsuchiya-Kawano; Tomonari Sasaki; Hiroyuki Yamaguchi; Katsuya Hirano; Atsushi Horiike; Miyako Satouchi; Shinobu Hosokawa; Ryotaro Morinaga; Kazutoshi Komiya; Koji Inoue; Yuka Fujita; Ryo Toyozawa; Tomoki Kimura; Kosuke Takahashi; Kazuo Nishikawa; Junji Kishimoto; Yoichi Nakanishi; Isamu Okamoto
Journal:  Oncologist       Date:  2019-10-24

Review 4.  [Results of N1 and N2 surgery in non-small cell lung cancer].

Authors:  J Pfannschmidt; J Kollmeier
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

5.  Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis.

Authors:  K A Khan; M P Kennedy; E Moore; L Crush; S Prendeville; M M Maher; L Burke; M T Henry
Journal:  Lung       Date:  2014-11-09       Impact factor: 2.584

6.  Serum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC.

Authors:  Fengming Lan; Xiao Yue; Gang Ren; Yingjie Wang; Tingyi Xia
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

7.  Quantitative Analysis of Radiation-Associated Parenchymal Lung Change.

Authors:  Edward Chandy; Adam Szmul; Alkisti Stavropoulou; Joseph Jacob; Catarina Veiga; David Landau; James Wilson; Sarah Gulliford; John D Fenwick; Maria A Hawkins; Crispin Hiley; Jamie R McClelland
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

Review 8.  Emerging developments of chemoradiotherapy in stage III NSCLC.

Authors:  Allan Price
Journal:  Nat Rev Clin Oncol       Date:  2012-08-28       Impact factor: 66.675

9.  Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.

Authors:  Hongmei Wang; Zhongxing Liao; Yan Zhuang; Ting Xu; Quynh-Nhu Nguyen; Lawrence B Levy; Michael O'Reilly; Kathryn A Gold; Daniel R Gomez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-22       Impact factor: 7.038

10.  Clinical efficacy of CyberKnife combined with chemotherapy and hyperthermia for advanced non-small cell lung cancer.

Authors:  Yuan-Yuan Wang; Si-Xiang Lin; Gui-Qing Yang; Han-Chen Liu; Dong-Ning Sun; Yi-Shan Wang
Journal:  Mol Clin Oncol       Date:  2013-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.